EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia

Elias Jabbour iD, Gerhard Zugmaier, Vaibhav Agrawal iD, Pilar Martínez-Sánchez, José J Rifón Roca, Ryan D Cassaday iD, Boris Böll, Anita Rijneveld, Maher Abdul-Hay, Françoise Huguet, Thomas Cluzeau, Mar Tormo Díaz und 15 weitere

American Journal of Hematology · 2024-04 · 99 (4) · 586-595

DOI: 10.1002/ajh.27227 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, online erschienen am 05.02.2024. Verfasst von Elias Jabbour und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Precursor Cell Lymphoblastic Leukemia-Lymphoma, Antibodies, Bispecific, Lymphoma, B-Cell, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 67-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Amgen Astellas Biopharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Blinatumomab is a BiTE® (bispecific T‐cell engager) molecule that redirects CD3 + T‐cells to engage and lyse CD19 + target cells. Here we demonstrate that subcutaneous (SC) blinatumomab can provide high efficacy and greater convenience of administration. In the expansion phase of a multi‐institutional phase 1b trial (ClinicalTrials.gov, NCT04521231), heavily pretreated adults with relapsed/refractory B‐cell acute lymphoblastic leukemia (R/R B‐ALL) received SC blinatumomab at two doses: (1) 250 μg once daily (QD) for week 1 and 500 μg three times weekly (TIW) thereafter (250 μg/500 μg) or (2) 500 μg QD for week 1 and 1000 μg TIW thereafter (500 μg/1000 μg). The primary endpoint was complete remission/complete remission with partial hematologic recovery (CR/CRh) within two cycles. At the data cutoff of September 15, 2023, 29 patients were treated: 14 at the 250 μg/500 μg dose and 13 at 500 μg/1000 μg dose. Data from two ineligible patients were excluded. At the end of two cycles, 12 of 14 patients (85.7%) from the 250 μg/500 μg dose achieved CR/CRh of which nine patients (75.0%) were negative for measurable residual disease (MRD;

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precursor Cell Lymphoblastic Leukemia-LymphomaAntibodies, BispecificLymphoma, B-CellPrecursor B-Cell Lymphoblastic Leukemia-LymphomaAntineoplastic AgentsAdultHumansRemission InductionPathologic Complete ResponseAcute DiseaseNeoplasm, Residual

Substanzen

blinatumomabAntibodies, BispecificAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Amgen Research (Munich), GmbH, Munich, Germany.
  • Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope National Medical Center, Duarte, California, USA.
  • Department of Hematology, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), CNIO, CIBERONC, Madrid, Spain.
  • Hematology and Hemotherapy Department, Clínica Universidad de Navarra, Pamplona, Spain.
  • Division of Hematology and Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, Washington, USA.

ORCID-Profile: Elias Jabbour, Vaibhav Agrawal, Ryan D Cassaday, Jesús María Hernández-Rivas, Hagop Kantarjian

Förderung

  • Amgen Astellas Biopharma

Zitieren

APA

Jabbour, E., Zugmaier, G., Agrawal, V., Martínez-Sánchez, P., Rifón Roca, J. J., Cassaday, R. D., Böll, B., Rijneveld, A., Abdul-Hay, M., Huguet, F., Cluzeau, T., Díaz, M. T., Vucinic, V., González-Campos, J., Rambaldi, A., Schwartz, S., Berthon, C., Hernández-Rivas, J. M., Gordon, P. R., …, & Kantarjian, H. (2024). Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia. American Journal of Hematology, 99(4), 586-595. https://doi.org/10.1002/ajh.27227

Vancouver

Jabbour E, Zugmaier G, Agrawal V, Martínez-Sánchez P, Rifón Roca JJ, Cassaday RD, et al. Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia. American Journal of Hematology. 2024;99(4):586-595. doi:10.1002/ajh.27227

BibTeX
@article{Jabbour2024,
  author = {Jabbour, Elias and Zugmaier, Gerhard and Agrawal, Vaibhav and Martínez-Sánchez, Pilar and Rifón Roca, José J and Cassaday, Ryan D and Böll, Boris and Rijneveld, Anita and Abdul-Hay, Maher and Huguet, Françoise and Cluzeau, Thomas and Díaz, Mar Tormo and Vucinic, Vladan and González-Campos, José and Rambaldi, Alessandro and Schwartz, Stefan and Berthon, Céline and Hernández-Rivas, Jesús María and Gordon, Paul R and Brüggemann, Monika and Hamidi, Ali and Chen, Yuqi and Wong, Hansen L and Panwar, Bharat and Katlinskaya, Yuliya and Markovic, Ana and Kantarjian, Hagop},
  title = {Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia},
  journal = {American Journal of Hematology},
  year = {2024},
  volume = {99},
  number = {4},
  pages = {586--595},
  doi = {10.1002/ajh.27227}
}
Kostenlos starten →